查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2117023

標靶放射性藥物市場：依產品類型、應用、最終用戶、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Targeted Radiopharmaceutical Market, By Product Type, By Application, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 361 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，標靶放射性藥物市場價值將達到 51.087 億美元，並將在 2026 年至 2033 年期間以 10.9% 的複合年成長率成長。

標靶放射性藥物屬於精準醫療的一個特殊類別，其原理是將放射性同位素與標靶特定組織的分子結合。標靶放射性藥物市場涵蓋診斷用PET和SPECT顯像劑、治療放射性配體、放射性核種前驅物、產生器、放射性標記裝置以及契約製造和管理服務。其主要應用領域是腫瘤學，特別是前列腺癌和神經內分泌腫瘤，但在循環系統和神經病學領域也有重要的應用。然而，由於許多同位素的半衰期較短，其生產、無菌儲存、運輸和醫療設備是供應鏈中的關鍵環節。預計到2025年，美國醫院每天將在診斷程序中使用約4萬劑鉬-99同位素。因此，同位素的供應在靶向放射性藥物領域發揮著至關重要的作用，它不僅滿足了新分子和細胞標靶的研發需求，還提供了顯著的競爭優勢。

標靶放射性藥物市場－市場動態

治療診斷學正在重新定義精準醫療的路徑。

分子影像與標靶治療的結合正推動精準腫瘤學走向更一體化的發展。治療診斷學平台旨在利用診斷影像技術識別腫瘤中表達特定標靶的患者，然後使用特異性相同受體的治療診斷學製劑對這些患者進行治療。因此，這些方法的發展推動了對伴隨診斷、同位素供應鏈、放射化學基礎設施、劑量測定和專業治療中心的需求。 2025年3月，FDA核准了「Pluvicto」用於治療先前接受過雄性素受體路徑抑制劑治療的PSMA陽性轉移性去勢抗性前列腺癌患者。此外，「PSMAfore」試驗證實，與對照治療相比，放射學進展或死亡風險降低了59%，這進一步強化了早期採用分子指導放射性配體療法的合理性，並促進了治療診斷學市場的成長。

標靶放射性藥物市場—區域分析

北美憑藉其強大的製藥公司、生物技術研發企業、學術核醫中心、國家同位素計畫和專業生產設施網路，在放射性藥物市場佔據領先地位。放射性藥物市場高度依賴短半衰期同位素的穩定供應，對延遲、供應中斷和庫存管理錯誤容忍度極低。全部區域的政策制定者和製藥公司正優先發展國內同位素生產和放射性配體製造能力，以確保醫用同位素供應不間斷。截至2025年，美國每天生產4萬劑鉬-99診斷劑量，反映了該地區核醫的高普及率。因此，北美能夠充分受益於全球核醫學的進步，同時也是新療法研發的驅動力。

歐洲靶向放射性藥物市場依賴現有的核子醫學基礎設施、製藥專業知識、研究設施和相關法規。此外，該地區放射性藥物生產和分銷缺乏集中管控，使得供應鏈至關重要。同時，同位素使用的時間限制也要求建立高效率的分銷網路。例如，2025年4月，歐洲藥品管理局（EMA）和各國藥品監管機構負責人就歐盟放射性藥物供應狀況發布了建議。這表明，透過監管協調、高藥物生產能力​​以及多層次的積極措施，該地區最有能力應對此類危機。

目錄

第1章：靶向放射性藥物市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：標靶放射性藥物的關鍵市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：靶向放射性藥物產業的分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章 針對放射性藥物市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：標靶放射性藥物的市場趨勢

  • 標靶放射性藥物市場佔有率分析，2025年
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 標靶放射性藥物市場：依產品類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按產品類型
    • 診斷用放射性藥物
      • 用於PET掃描的放射性藥物
      • 用於SPECT的放射性藥物
    • 用於治療的放射性藥物
      • BETA射線發射型
      • α粒子發射型
      • 其他

第8章 標靶放射性藥物市場：依應用領域分類

  • 概述
    • 基於細分市場的市場佔有率分析：按應用領域
    • 腫瘤學
    • 循環系統
    • 神經病學
    • 內分泌科/甲狀腺
    • 其他

第9章 標靶放射性藥物市場：依最終用戶分類

  • 概述
    • 基於細分市場的市場佔有率分析：按最終用戶分類
    • 醫院和診所
    • 診斷影像中心
    • 核子醫學中心
    • 癌症治療中心
    • 學術研究機構
    • 其他

第10章 標靶放射性藥物市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第11章：主要供應商分析：目標放射性藥物產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Novartis AG
    • Lantheus Holdings, Inc.
    • Curium Pharma
    • GE HealthCare
    • Bayer AG
    • AstraZeneca plc
    • Eli Lilly and Company
    • Bristol Myers Squibb
    • ITM Isotope Technologies Munich SE
    • Telix Pharmaceuticals Limited
    • Bracco Imaging SpA
    • Clarity Pharmaceuticals Ltd.
    • Eckert & Ziegler SE
    • Actinium Pharmaceuticals, Inc.
    • Evergreen Theragnostics, Inc.
    • Siemens Healthineers AG
    • Cardinal Health, Inc.
    • Boehringer Ingelheim International GmbH
    • Perspective Therapeutics, Inc.
    • RadioMedix, Inc.
    • NorthStar Medical Radioisotopes
    • Others

第12章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7304

Targeted Radiopharmaceutical Market size was valued at US$ 5,108.7 Million in 2025, expanding at a CAGR of 10.9% from 2026 to 2033.

Targeted radiopharmaceuticals represent a special category of precision medicines that involve attaching a radioactive isotope to molecules that specifically target certain tissues. The targeted radiopharmaceuticals market consists of diagnostic PET and SPECT agents, therapeutic radioligands, radionuclide precursors, generators, radiolabeling equipment, and contract manufacturing and control services. The main area of application is oncology, primarily prostate cancer and neuroendocrine tumors, but there are also significant applications in cardiology and neurology. At the same time, the short half-lives of many isotopes mean that their production, sterile storage, transportation, and medical equipment are important aspects of the supply chain. In 2025, U.S. hospitals used approximately 40,000 doses of the isotope Mo-99 every day in diagnostic procedures. Therefore, the availability of isotopes plays an essential role in targeted radiopharmaceuticals, complementing the need to develop new molecules and cell targets, and is a major competitive advantage.

Targeted Radiopharmaceutical Market- Market Dynamics

Theranostics Is Reshaping Precision Treatment Pathways

The combination of molecular imaging and targeted therapy is leading to a more integrated approach to precision oncology. Theranostic platforms are designed to utilize diagnostic imaging to identify patients with tumor expression of a given target and then treat those patients with a theranostic agent that specifically targets the same receptor. As such, the development of these approaches is driving need for companion diagnostics, isotope supply chains, radiochemistry infrastructure, dosimetry, and specialized treatment centers. In March 2025, the FDA approved Pluvicto for use in patients with PSMA-positive metastatic castration-resistant prostate cancer who had received an androgen-receptor pathway inhibitor, and the PSMAfore trial saw a 59% reduction in the risk of radiographic progression or death from the control treatment, further bolstering the case for earlier molecularly guided radioligand treatment and supporting the growth of the theranostics market.

Targeted Radiopharmaceutical Market- Geographical Insights

North America is the leading radiopharmaceuticals market due to the strong network of pharmaceutical companies, biotech developers, academic nuclear-medicine centers, national isotope programs, and specialized manufacturing facilities. The radiopharmaceuticals market is highly dependent on the stable supply of short-lived isotopes, offers limited scope for delays, disruptions, and inventory management errors. Policymakers and pharmaceutical companies throughout the region are prioritizing the development of domestic isotope production capabilities and radioligand manufacturing to ensure an uninterrupted supply of medical isotopes. As of 2025, there are 40000 Mo-99 diagnostic doses produced daily in the US, which underlines the level of nuclear medicine adoption in the region. North America is therefore strongly positioned to benefit from the worldwide in nuclear medicine while also being the driving force behind the development of novel therapeutics.

Europe's targeted radiopharmaceutical landscape is supported by the existing nuclear-medicine infrastructure, pharma expertise, research facilities, and regulations. The region also lacks centralized control over radiopharmaceutical production and distribution, meaning the supply chain is of utmost importance. Moreover, time constraints for isotope use require efficient distribution networks. For example, in April 2025, the European Medicines Agency and Heads of Medicines Agencies released recommendations concerning the radiopharmaceutical supply situation in the EU. This shows that the region has the best conditions to manage and respond to such crises because of the harmonization of regulations, high pharma production capabilities, and proactive measures at multiple levels.

Targeted Radiopharmaceutical Market- Competitive Landscape:

Competition in targeted radiopharmaceuticals market is now focusing on broader areas from target discovery, access to radionuclides, radiochemistry, manufacturing, and clinical development to distribution. Thus, Novartis has developed a comprehensive radioligand platform, while competitors, including Bayer, Lantheus, Curium, and new biotech companies, are positioning themselves to provide diverse products and technologies in therapeutics, diagnostics, manufacturing, and specific areas of radiochemistry. Moreover, the overall capacity of production is critical, as radiopharmaceutical requires a stable and reliable supply chain that produces medicines with a short shelf life. Therefore, Novartis opened its third U.S. radioligand manufacturing facility in the Los Angeles area in November 2025. Hence, the ability to deliver complex radioligands to the clinic reliably allows Novartis to differentiate itself from competitors and provide a consistent supply of medicinal products for clinical partners and patients worldwide.

Recent Developments:

March 2025, Novartis: The U.S. FDA expanded the indication of Pluvicto for patients with PSMA-positive metastatic castration-resistant prostate cancer who had received androgen-receptor pathway inhibitor therapy and were treatment-naive in the second-line setting. The new indication moved radioligand therapy to an earlier treatment paradigm and extended the indication to a broader patient population.

In November 2025, Novartis opened a new 10,000-square-foot radioligand manufacturing facility in Carlsbad, California. This new U.S. radioligand production site is the company's third in the U.S. The new facility will help meet the needs of manufacturing these complex therapies while supporting the time-sensitive nature of radiolabeled compounds

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TARGETED RADIOPHARMACEUTICAL MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis AG
  • Lantheus Holdings, Inc.
  • Curium Pharma
  • GE HealthCare
  • Bayer AG
  • AstraZeneca plc
  • Eli Lilly and Company
  • Bristol Myers Squibb
  • ITM Isotope Technologies Munich SE
  • Telix Pharmaceuticals Limited
  • Bracco Imaging S.p.A.
  • Clarity Pharmaceuticals Ltd.
  • Eckert & Ziegler SE
  • Actinium Pharmaceuticals, Inc.
  • Evergreen Theragnostics, Inc.
  • Siemens Healthineers AG
  • Cardinal Health, Inc.
  • Boehringer Ingelheim International GmbH
  • Perspective Therapeutics, Inc.
  • RadioMedix, Inc.
  • NorthStar Medical Radioisotopes
  • Others

GLOBAL TARGETED RADIOPHARMACEUTICAL MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2020 - 2033

  • Diagnostic Radiopharmaceuticals
  • PET Radiopharmaceuticals
  • SPECT Radiopharmaceuticals
  • Therapeutic Radiopharmaceuticals
  • Beta-Emitting
  • Alpha-Emitting
  • Others

GLOBAL TARGETED RADIOPHARMACEUTICAL MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033

  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology / Thyroid
  • Others

GLOBAL TARGETED RADIOPHARMACEUTICAL MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Hospitals & Clinics
  • Diagnostic Imaging Centers
  • Nuclear Medicine Centers
  • Cancer Treatment Centers
  • Academic & Research Institutes
  • Others

GLOBAL TARGETED RADIOPHARMACEUTICAL MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Targeted Radiopharmaceutical Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Targeted Radiopharmaceutical Market Snippet by Product Type
    • 2.1.2. Targeted Radiopharmaceutical Market Snippet by Application
    • 2.1.3. Targeted Radiopharmaceutical Market Snippet by End User
    • 2.1.4. Targeted Radiopharmaceutical Market Snippet by Country
    • 2.1.5. Targeted Radiopharmaceutical Market Snippet by Region
  • 2.2. Competitive Insights

3. Targeted Radiopharmaceutical Key Market Trends

  • 3.1. Targeted Radiopharmaceutical Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Targeted Radiopharmaceutical Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Targeted Radiopharmaceutical Market Opportunities
  • 3.4. Targeted Radiopharmaceutical Market Future Trends

4. Targeted Radiopharmaceutical Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Targeted Radiopharmaceutical Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Targeted Radiopharmaceutical Market Landscape

  • 6.1. Targeted Radiopharmaceutical Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Targeted Radiopharmaceutical Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2025 & 2033 (%)
    • 7.1.2. Diagnostic Radiopharmaceuticals
      • 7.1.2.1. PET Radiopharmaceuticals
      • 7.1.2.2. SPECT Radiopharmaceuticals
    • 7.1.3. Therapeutic Radiopharmaceuticals
      • 7.1.3.1. Beta-Emitting
      • 7.1.3.2. Alpha-Emitting
      • 7.1.3.3. Others

8. Targeted Radiopharmaceutical Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
    • 8.1.2. Oncology
    • 8.1.3. Cardiology
    • 8.1.4. Neurology
    • 8.1.5. Endocrinology / Thyroid
    • 8.1.6. Others

9. Targeted Radiopharmaceutical Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
    • 9.1.2. Hospitals & Clinics
    • 9.1.3. Diagnostic Imaging Centers
    • 9.1.4. Nuclear Medicine Centers
    • 9.1.5. Cancer Treatment Centers
    • 9.1.6. Academic & Research Institutes
    • 9.1.7. Others

10. Targeted Radiopharmaceutical Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Targeted Radiopharmaceutical Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Targeted Radiopharmaceutical Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.16. Denmark
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.16.3. Denmark Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.16.4. Denmark Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.16.5. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.3.17. Rest of Europe
      • 10.3.17.1. Overview
      • 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.3.17.5. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Targeted Radiopharmaceutical Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.15. Taiwan
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.15.3. Taiwan Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.15.4. Taiwan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.15.5. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.16. Vietnam
      • 10.4.16.1. Overview
      • 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.16.3. Vietnam Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.16.4. Vietnam Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.16.5. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.4.17. Rest of APAC
      • 10.4.17.1. Overview
      • 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.4.17.3. Rest of APAC Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.4.17.4. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.4.17.5. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Targeted Radiopharmaceutical Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Targeted Radiopharmaceutical Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.13. Iran
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.13.3. Iran Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.13.4. Iran Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.13.5. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.14. Qatar
      • 10.6.14.1. Overview
      • 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.14.3. Qatar Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.14.4. Qatar Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.14.5. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 10.6.15. Rest of MEA
      • 10.6.15.1. Overview
      • 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 10.6.15.3. Rest of MEA Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 10.6.15.4. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
      • 10.6.15.5. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

11. Key Vendor Analysis- Targeted Radiopharmaceutical Industry

  • 11.1. Competitive Benchmarking
    • 11.1.1. Competitive Dashboard
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Novartis AG
    • 11.2.2. Lantheus Holdings, Inc.
    • 11.2.3. Curium Pharma
    • 11.2.4. GE HealthCare
    • 11.2.5. Bayer AG
    • 11.2.6. AstraZeneca plc
    • 11.2.7. Eli Lilly and Company
    • 11.2.8. Bristol Myers Squibb
    • 11.2.9. ITM Isotope Technologies Munich SE
    • 11.2.10. Telix Pharmaceuticals Limited
    • 11.2.11. Bracco Imaging S.p.A.
    • 11.2.12. Clarity Pharmaceuticals Ltd.
    • 11.2.13. Eckert & Ziegler SE
    • 11.2.14. Actinium Pharmaceuticals, Inc.
    • 11.2.15. Evergreen Theragnostics, Inc.
    • 11.2.16. Siemens Healthineers AG
    • 11.2.17. Cardinal Health, Inc.
    • 11.2.18. Boehringer Ingelheim International GmbH
    • 11.2.19. Perspective Therapeutics, Inc.
    • 11.2.20. RadioMedix, Inc.
    • 11.2.21. NorthStar Medical Radioisotopes
    • 11.2.22. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us